Search is Powered by Google
Cancer / Oncology News

Patients Overestimate Cancer Screening History

Main Category: Cancer / Oncology
Also Included In: Women's Health / Gynecology
Article Date: 21 Apr 2008 - 2:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

A new American Cancer Society study finds female African American patients tend to overestimate their level of cancer screening, indicating that current estimates of screening based on self-reported data may be lower than reported.

Researchers from the Society's Behavioral Research Center, led by Barbara D. Powe, PhD, RN, interviewed 116 African American female patients at a federally qualified health center (FQHC) and compared their recollection to the screening history documented in the patients' medical records for four medical tests: clinical breast examination; mammography; Pap testing; and screening with a fecal occult blood test (FOBT). They found the level of incongruence between self-report and medical record documentation was more than 50 percent for some procedures.

Eighty-six percent of the women who were age 20 or older (n = 94) reported having a CBE in their lifetime, 67 percent in the past year, 20 percent in the past two to five years, and 10 percent more than five years ago. Based on medical record documentation, 35 percent of the women had a CBE in their lifetime, 26 percent in the past year, 4 percent in the past two to five years, and 2 percent more than five years ago.

Seventy-seven percent of the women over 40 (n=35) reported ever having a mammogram in their lifetime, 29 percent in the past year, 29 percent in the past two to five years, and 6 percent more than five years ago. Based on documentation in the medical record, 40 percent of the women had a mammogram in their lifetime, 9 percent in the past year, 26 percent in the past two to five years, and 6 percent more than five years ago.

Of the 43 women asked about Pap test use, 96 percent reported having had a Pap test in their lifetime, 72 percent in the past year, 26 percent in the past two to five years, and 12 percent more than five years ago. Based on documentation in the medical record, 58 percent of the women had a Pap test in their lifetime, 39 percent in the past year, 25 percent in the past two to five years, and 13 percent more than five years ago.

Fifty-six percent of the women over 50 (n=16) reported ever having a fecal occult blood test (FOBT) in their lifetime, 35 percent in the past year, 12 percent in the past two to five years, and 6 percent more than five years ago. Based on documentation in the medical record, 11 percent of the women had a FOBT in their lifetime, 12 percent in the past year, and 0 percent in the past two to five years or more than five years ago.

The researchers acknowledge that the women could have received services without documentation in the medical record or that the women could have mistakenly believed a clinical service included screening when it did not. Nevertheless, they cite previous research that also has found patients tend to over-report their level of screening.

The authors say maintaining efforts to effectively monitor and track participation in cancer screening among African Americans and other groups should be a priority, offering the electronic medical record as one way to ensure more accurate medical documentation. "Self-reported screening rates are the foundation for many policy decisions that have a significant influence on the availability of resources for this population," said Dr. Powe. "Indeed, over- or underestimation of screening can be even more significant for African Americans, who bear a disproportionate cancer burden."

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Article: Oncology Nursing Forum, March 2008, pp. 199-204.

The American Cancer Society is dedicated to eliminating cancer as a major health problem by saving lives, diminishing suffering and preventing cancer through research, education, advocacy and service. Founded in 1913 and with national headquarters in Atlanta, the Society has 13 regional Divisions and local offices in 3,400 communities, involving millions of volunteers across the United States. For more information visit http://www.cancer.org/.

Source: David Sampson
American Cancer Society




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...